Optimal Antiplatelet Therapy In NSTE-ACS: Results From A Novel Crowdsourcing Survey
The choice and duration of antiplatelet therapy in NSTE-ACS undergoing PCI is complex and is a hotly debated topic – particularly amongst patients at high bleeding risk. To gain insight into the real-world practices of a global cross-section of cardiologists, Radcliffe Medical Education, in partnership with the International Society of Cardiovascular Pharmacotherapy (ISCP), undertook a novel crowdsourcing project to capture their prevailing beliefs and practices in antiplatelet treatment, in patients at high bleeding risk.
We reported our findings in a paper recently published in the International Journal of Cardiology and are delighted to now bring you a roundtable discussion, featuring members of the steering committee, to further explain the project, the main findings, and the potential implications for future research.
To view the article please click here
To view the questions asked in the survey please click to 'download slides'.
This project was made possible by an unrestricted educational grant from AstraZeneca.
Juan Carlos Kaski
Dominick J Angiolillo
This webinar is supported by:
Juan Carlos Kaski
* Welcome and Introductions
* Unmet needs in high bleeding risk patients
* Rationale for the research
* Overarching trends
* Observations of interest
* Clinical implications
* Future applications
Key Learning Objectives
- Describe current guideline-led recommendations for the use and duration of dual antiplatelet therapy in NSTE-ACS patients at high bleeding risk
- Explain how alternative antiplatelet strategies differ to those advocated in current international guidelines for high bleeding risk individuals
- Recall how practice varied in prescribers who took part in the crowdsourcing project
- Describe how a crowdsourcing methodology may have potential implications for future research
Research Data Gathered From
- 559 respondents
- 70 countries
- Specialisms included interventional cardiologists, non-invasive cardiologists and other prescribers
- Physician representation from state and public hospitals, private hospitals, university and teaching hospitals plus research institutes
Juan Carlos Kaski
Juan Carlos Kaski is Professor of Cardiovascular Science (Emeritus) at the Molecular and Clinical Sciences Research Institute, St Gorge’s, University of London, and Hon. Consultant Cardiologist at St George’s Hospital and the Royal Brompton Hospital in London, UK. He is Doctor Honoris Causa of several universities worldwide, a past-President of the International Society of Cardiovascular Pharmacotherapy and Fellow of over 30 scientific societies worldwide. JC Kaski has received numerous national and international awards for his research work and both his clinical and educational activities. Professor Kaski is Chairman-elect, European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Editor-in-Chief of the European Cardiology Review Journal, Deputy Editor of the European Heart Journal, Co-Editor of the ESC Handbook on Cardiovascular Pharmacotherapy and editorial board member of JACC and over 20 other scientific journals. Prof Kaski’s research areas include inflammatory and immunological mechanisms of atherosclerosis, microvascular and vasospastic angina, INOCA and MINOCA, biomarkers of cardiovascular risk and management of angina pectoris. He has authored over 600 scientific papers on these topics in peer review journals and edited 10 books.
Deepak L. Bhatt MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.
Dr Bhatt has over 1600 publications and has been listed by the Web of Science as a Highly Cited Researcher.
He is the Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.
Felicita Andreotti, MD, PhD, is a tenured Professor and Medical Director at the Gemelli IRCCS Hospital and Catholic University in Rome, Italy, where she currently coordinates cardiovascular research within the Scientific Directorate.
Professor Andreotti gained her MD and two Specialties - in respiratory and cardiac diseases - from the University of Strasbourg, France, and then Pisa, Italy. During her PhD work in Leiden, NL, and a Lectureship in London, UK, she investigated the fibrinolytic/haemostatic system in health and disease, with funding from the British and Dutch Heart Foundations.
Professor Andreotti has contributed to 20 European Society of Cardiology (ESC) clinical practice guidelines or position papers, chaired the ESC working group on Thrombosis, and coordinated multicenter studies funded by the Italian Ministry of Research.
She has authored over 300 articles in peer-reviewed journals, including N Engl J Med, JAMA, Lancet and Brit Med J. She is currently Deputy Editor of the Eur Heart J, member of data safety monitoring boards of international phase III trials, and co-founder of the J Thromb Thrombolysis. Her Scopus H index (as of May 2021) is 60.
Dominick J Angiolillo
Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology.
In 2004, Dr Angiolillo joined the University of Florida College of Medicine – Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program.
Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his own textbook on antithrombotic medicine.